Clinical use of serum and urine bone markers in the management of osteoporosis

Current Medical Research and Opinion

Volumn 21, Issue 7, 2005, Pages 1015-1026

  Srivastava, Apurva K ^a,b   Vliet, Elizabeth L ^c   Lewiecki, E Michael ^d   Maricic, Michael ^e,f   Abdelmalek, Alex ^g,h   Gluck, Oscar ⁱ   Baylink, David J ^a,b  

^a Jerry L Pettis Memorial VA Medical Center   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^d Health Enhancement Renewal for Women Inc   (United States)

^e SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

Author keywords

Bone markers; Bone remodeling; Bone turnover; Osteopenia; Osteoporosis

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; COLLAGEN TYPE 1; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALGORITHM; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; CLINICAL PRACTICE; FRACTURE; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN URINE LEVEL; REIMBURSEMENT; REVIEW;

BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOPOROSIS; PROGNOSIS;

EID: 22744440767     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X49635     Document Type: Review

References (70)

1. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost effective analysis. Osteoporosis Int 1998;8:S1-S88
2. NIH Consensus Development Panel on Osteoporosis. J Am Med Assoc 2001;285:785-95
3. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50
4. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. WHO Technical Report Series 843, Geneva, Switzerland: World Health Organization; 1994. p. 1-129
5. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures [The Study of Osteoporotic Fractures Research Group]. Lancet 1993;341:72-5
6. Burr DB. Introduction - bone turnover and fracture risk. J Musculoskeletal Neuron Interact 2003;3(4):408-9
7. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9
8. Sarkar S, Mitlak BH, Wong M, Stock J, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10
9. Heaney RP. Is the paradigm shifting? Bone 2003;3(4):457-65
10. Riggs BL, Melton III LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decrease in vertebral fractures without commensurate increase in bone density. J Bone Miner Res 2002;17:11-4
11. Melton LJ, Khosla S, Atkinson EJ, O'Fallon WO, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-91
12. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on hip. Osteoporosis Int 2002;13:349-52
13. Sarkar S, Reginster J, Crans GG, Diez-Perez A, Pinette Karen V, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19(3):394-401
14. Bauer, DC, Black DM, Garnero, P, et al., for the Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19(8):1250-8
15. Parfitt AM. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J Bone Miner Res 2002;17(8):1558-9 [discussion 1560]
16. Miller PD, Baran DT, Bilezekian J, et al. Practical clinical applications of biochemical markers of bone turnover. J Clin Densitometry 1999;2(3):323-42
17. Agerbaek MO, Eriksen EF, Kragstrup J, Mosekilde L, Melsen F. A reconstruction of the remodeling cycle in normal human cortical iliac bone. Bone Miner 1991;12(2):101-12
18. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37
19. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7(11):1251-8
20. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40(11):2022-5
21. Bettica P, Taylor AK, Talbot J, Talamani R, Baylink DJ. Clinical performance of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996;81:542-6
22. Boivin G, Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002;70(6):3-11
23. Einhorn TA. Bone strength: the bottom line. Calcif Tissue Int 51;1992:333-9
24. Parfitt AM. Use of bisphosphonates in the prevention of bone loss and fractures. Am J Med 1991;91(5B):42S-46S
25. Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 2000;15(7): 1368-75
26. Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 2000;15(1):13-9
27. Chestnut CH, Clark GS, English SC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type-I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37
28. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13(2):297-302
29. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14(9): 1614-21
30. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11(10):1531-8
31. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial [FIT Research Group]. J Clin Endocrinol Metab 2000;85(11):4118-24
32. Reginster JY, Minne HW, Sorenson OH, et al. Randomized trial of the effects of residronate on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy With Residronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282(14): 1344-52
33. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-45
34. Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [PROOF Study Group]. Am J Med 2000;109(4):267-76
35. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18(6):1051-6
36. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87(4):1586-92
37. Dobing H, Fahrleitner A, Ste-Marie L, et al. Early changes in biochemical markers of bone formation predict improvements in bone structure during teriparatide therapy. 85th Annual Meeting of The Endocrine Society, Program & Abstracts, 2003. p. 131
38. Braga de Castro-Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14(4):602-8
39. Raisz L, Smith JA, Trahiotis M, et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 2000;11(7):615-20
40. Medicare program; negotiated rulemaking: coverage and administrative policies for clinical diagnostic laboratory services; final rule. November 23, 2001, [66 FR 58843-58846]
41. Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003;18(10):1789-94
42. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 2000;11(5):434-42
43. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001;16(1):157-65
44. Akesson K, Ljunghall S, Jonsson B, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995;10(11):1823-9
45. Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 1999;4(8):1449-56
46. Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou EA. Randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002;17(3):521-7
47. Srivastava AK, Libanati C, Hohmann O, Kriegman A, J Baylink DJ. Effects of calcitonin nasal spray on serum C-telopeptide levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int 2004;75:477-81
48. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev CD000011, 2000
49. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26(2):245-56
50. Davies GC, Huster WJ, Lu Y, Plouffe Jr L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-65
51. Recker RR, Gallagher R, Amonkar M, Smith JC, MacCosbe PE. Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. Poster SA407, presented at: 26th Annual Meeting of the American Society for Bone Mineral Research, October 1-5, 2004, Seattle, WA
52. Clowes JA, Peel NFA, Eastell R. The effect of monitoring on adherence and persistence with raloxifene therapy and the impact of the effectiveness of treatment. J Bone Miner Res 2002;17(Suppl 1):S155
53. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89(3):1117-23
54. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Presented at the 30th European Symposium on Calcified Tissues, May 8-12, 2003, Rome, Italy
55. Delmas PD, Vrijens B, Roux C, et al. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res. 2003;18(Suppl 2):S374
56. The Swedish Council on Technology Assessment in Health Care. Bone density measurement - a systematic review: a report from SBU. J Intern Med 1997;241(Suppl 739):5-11,12-22,42-4
57. Assessment of osteoporotic fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129
58. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17(1):1-36
59. Physician's Guide to Prevention and Treatment of Osteoporosis. 2nd ed. Washington, DC: National Osteoporosis Foundation; 2003. Position statement: executive summary
60. Unites States Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137(6):526-8. Source description. Available from www.ahrq.gov/clinic/ epcsums/osteosum.htm
61. The Writing Group for the International Society for Clinical Densitometry (ISCD) Position Development Conference. J Clin Densitom. 2004;7:7-12
62. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815-22
63. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13(7):1124-33
64. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15(3):594-8
65. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporosis Int 2000; 11 Suppl 6: S30-44
66. Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem 2002;48(2):220-35
67. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31(1):57-61
68. South-Paul JE. Osteoporosis Part I. Evaluation and Assessment. Am Family Phy 2001;63(5):897-904
69. Nishizawa Y, Nakamura T, Ohata H, et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone & Miner Metabolism 2001;19:338-44
70. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41